Global Aphakia Market Size, Share, Forecast Report, 2020-2027

Aphakia describes the absence or dislocation of the crystalline eye lens. It is the most commonly occurs due to the presence of diseases such as trauma and congenital conditions or after surgery for cataract removal. Increasing prevalence of diseases such as diabetes & trauma and increasing number of accident have boosted the market growth of the aphakia. According to World Health Organization (WHO), in 2014, 285 million people were visually impaired across the globe in which 246 million had low vision and 39 million were completely blind. Additionally, According to the WHO, 422 million people have diabetes and this number is increasing at the rate of 8.5%. Moreover, increasing geriatric population, rapidly developing healthcare sector, and increasing demand for the better treatment of the ophthalmic diseases fuel the market growth. On the other hand, the high cost of the surgery and limited availability of the treatment may slow the market growth.

The global aphakia market is expected to grow at a CAGR of ~9.2 % during the forecast period 2017-2023.
Segmentations

The global aphakia market has been segmented on the basis of types, causes, treatment, and end user.

On the basis of type, the market is segmented into primary, and secondary.

On the basis of cause, the market is categorized into congenital aphakia, surgical aphakia, acquired aphakia, and others. Acquired aphakia is further segmented into traumatic extrusion, posterior dislocation, couching, and other.

On the basis of treatment, the market is segmented into spectacles, contact lenses, intraocular lens implantation, refractive surgery, and others. The spectacles are sub-segmented into +10D, +3-4D, and other. Refractive surgery is further segmented into keratophakia, epikeratophakia, and hyperopic LASIK.

On the basis of end user, the market is segmented into hospitals, ophthalmic clinics, and others.
Key Players
Some of key the players in the market are Johnson & Johnson Services, Inc. (US), Ophtec BV (Netherland), Alcon Laboratories, Inc. (Switzerland‎), Bausch & Lomb (US), Carl Zeiss AG (Germany), Rayner Company (US), Bohus BioTech AB (Sweden), CooperVision, Inc. (US), Lifecore Biomedical, LLC (US), Aetna Inc. (US), Ciba Vision (Switzerland), and Menicon (Singapore).